APO Research
Talk to an analyst

APO RESEARCH · REPORT

Somatostatin Analogue Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Somatostatin Analogue Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025192 pages

Choose your research edition.

Industry ResearchSomatostatin Analogue Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Somatostatin Analogue Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Somatostatin Analogue Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Somatostatin Analogue Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Somatostatin Analogue Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Somatostatin Analogue Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Somatostatin Analogue Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Somatostatin Analogue Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Somatostatin Analogue Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Somatostatin Analogue Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Somatostatin Analogue Drug include Teva Pharmaceutical Industries Ltd., Novartis AG, Eli Lilly & Co., Pfizer Inc., Tarveda Therapeutics Inc., Ipsen Group, F. Hoffmann-La Roche Ltd., Chiasma and Camurus AB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Somatostatin Analogue Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Somatostatin Analogue Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Somatostatin Analogue Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Somatostatin Analogue Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Somatostatin Analogue Drug Segment by Company

Teva Pharmaceutical Industries Ltd.

Novartis AG

Eli Lilly & Co.

Pfizer Inc.

Tarveda Therapeutics Inc.

Ipsen Group

F. Hoffmann-La Roche Ltd.

Chiasma

Camurus AB

Boehringer Ingelheim International GmbH

Somatostatin Analogue Drug Segment by Type

Octreotide

Lanreotide

Pasireotide

Somatostatin Analogue Drug Segment by Application

Acromegaly

Neuroendocrine Tumor (NET)

Others

Somatostatin Analogue Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Somatostatin Analogue Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Somatostatin Analogue Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Somatostatin Analogue Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Somatostatin Analogue Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Somatostatin Analogue Drug industry.

Chapter 3: Detailed analysis of Somatostatin Analogue Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Somatostatin Analogue Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Somatostatin Analogue Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Octreotide Table 3. Key Players of Lanreotide Table 4. Key Players of Pasireotide Table 4. Global Somatostatin Analogue Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Acromegaly Table 6. Key Players of Neuroendocrine Tumor (NET) Table 7. Key Players of Others Table 8. Global Somatostatin Analogue Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Somatostatin Analogue Drug Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Somatostatin Analogue Drug Market Share by Region (2021-2026) Table 11. Global Somatostatin Analogue Drug Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Somatostatin Analogue Drug Market Share by Region (2027-2032) Table 13. Somatostatin Analogue Drug Industry Trends Table 14. Somatostatin Analogue Drug Industry Drivers Table 15. Somatostatin Analogue Drug Industry Opportunities and Challenges Table 16. Somatostatin Analogue Drug Industry Restraints Table 17. Global Somatostatin Analogue Drug Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Somatostatin Analogue Drug Revenue Market Share by Company (2021-2026) Table 19. Global Somatostatin Analogue Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Somatostatin Analogue Drug Key Company Head Office and Area Served Table 21. Global Somatostatin Analogue Drug Company, Product Type & Application Table 22. Global Somatostatin Analogue Drug Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Somatostatin Analogue Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Somatostatin Analogue Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Somatostatin Analogue Drug Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Somatostatin Analogue Drug Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Somatostatin Analogue Drug Revenue Market Share by Type (2021-2026) Table 29. Global Somatostatin Analogue Drug Revenue Market Share by Type (2027-2032) Table 30. Global Somatostatin Analogue Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Somatostatin Analogue Drug Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Somatostatin Analogue Drug Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Somatostatin Analogue Drug Revenue Market Share by Application (2021-2026) Table 34. Global Somatostatin Analogue Drug Revenue Market Share by Application (2027-2032) Table 35. Teva Pharmaceutical Industries Ltd. Company Information Table 36. Teva Pharmaceutical Industries Ltd. Business Overview Table 37. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product Portfolio Table 39. Teva Pharmaceutical Industries Ltd. Recent Development Table 40. Novartis AG Company Information Table 41. Novartis AG Business Overview Table 42. Novartis AG Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Novartis AG Somatostatin Analogue Drug Product Portfolio Table 44. Novartis AG Recent Development Table 45. Eli Lilly & Co. Company Information Table 46. Eli Lilly & Co. Business Overview Table 47. Eli Lilly & Co. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Eli Lilly & Co. Somatostatin Analogue Drug Product Portfolio Table 49. Eli Lilly & Co. Recent Development Table 50. Pfizer Inc. Company Information Table 51. Pfizer Inc. Business Overview Table 52. Pfizer Inc. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Pfizer Inc. Somatostatin Analogue Drug Product Portfolio Table 54. Pfizer Inc. Recent Development Table 55. Tarveda Therapeutics Inc. Company Information Table 56. Tarveda Therapeutics Inc. Business Overview Table 57. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product Portfolio Table 59. Tarveda Therapeutics Inc. Recent Development Table 60. Ipsen Group Company Information Table 61. Ipsen Group Business Overview Table 62. Ipsen Group Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Ipsen Group Somatostatin Analogue Drug Product Portfolio Table 64. Ipsen Group Recent Development Table 65. F. Hoffmann-La Roche Ltd. Company Information Table 66. F. Hoffmann-La Roche Ltd. Business Overview Table 67. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product Portfolio Table 69. F. Hoffmann-La Roche Ltd. Recent Development Table 70. Chiasma Company Information Table 71. Chiasma Business Overview Table 72. Chiasma Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Chiasma Somatostatin Analogue Drug Product Portfolio Table 74. Chiasma Recent Development Table 75. Camurus AB Company Information Table 76. Camurus AB Business Overview Table 77. Camurus AB Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Camurus AB Somatostatin Analogue Drug Product Portfolio Table 79. Camurus AB Recent Development Table 80. Boehringer Ingelheim International GmbH Company Information Table 81. Boehringer Ingelheim International GmbH Business Overview Table 82. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product Portfolio Table 84. Boehringer Ingelheim International GmbH Recent Development Table 85. North America Somatostatin Analogue Drug Market Size by Type (2021-2026) & (US$ Million) Table 86. North America Somatostatin Analogue Drug Market Size by Type (2027-2032) & (US$ Million) Table 87. North America Somatostatin Analogue Drug Market Size by Application (2021-2026) & (US$ Million) Table 88. North America Somatostatin Analogue Drug Market Size by Application (2027-2032) & (US$ Million) Table 89. North America Somatostatin Analogue Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America Somatostatin Analogue Drug Market Size by Country (2021-2026) Table 91. North America Somatostatin Analogue Drug Market Size by Country (2027-2032) Table 92. Europe Somatostatin Analogue Drug Market Size by Type (2021-2026) & (US$ Million) Table 93. Europe Somatostatin Analogue Drug Market Size by Type (2027-2032) & (US$ Million) Table 94. Europe Somatostatin Analogue Drug Market Size by Application (2021-2026) & (US$ Million) Table 95. Europe Somatostatin Analogue Drug Market Size by Application (2027-2032) & (US$ Million) Table 96. Europe Somatostatin Analogue Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe Somatostatin Analogue Drug Market Size by Country (2021-2026) Table 98. Europe Somatostatin Analogue Drug Market Size by Country (2027-2032) Table 99. China Somatostatin Analogue Drug Market Size by Type (2021-2026) & (US$ Million) Table 100. China Somatostatin Analogue Drug Market Size by Type (2027-2032) & (US$ Million) Table 101. China Somatostatin Analogue Drug Market Size by Application (2021-2026) & (US$ Million) Table 102. China Somatostatin Analogue Drug Market Size by Application (2027-2032) & (US$ Million) Table 103. Asia Somatostatin Analogue Drug Market Size by Type (2021-2026) & (US$ Million) Table 104. Asia Somatostatin Analogue Drug Market Size by Type (2027-2032) & (US$ Million) Table 105. Asia Somatostatin Analogue Drug Market Size by Application (2021-2026) & (US$ Million) Table 106. Asia Somatostatin Analogue Drug Market Size by Application (2027-2032) & (US$ Million) Table 107. Asia Somatostatin Analogue Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia Somatostatin Analogue Drug Market Size by Country (2021-2026) Table 109. Asia Somatostatin Analogue Drug Market Size by Country (2027-2032) Table 110. South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Type (2021-2026) & (US$ Million) Table 111. South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Type (2027-2032) & (US$ Million) Table 112. South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Application (2021-2026) & (US$ Million) Table 113. South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Application (2027-2032) & (US$ Million) Table 114. South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2021-2026) Table 116. South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Somatostatin Analogue Drug Product Image Figure 2. Global Somatostatin Analogue Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Somatostatin Analogue Drug Market Share by Type: 2025 VS 2032 Figure 4. Octreotide Image Figure 5. Lanreotide Image Figure 6. Pasireotide Image Figure 7. Global Somatostatin Analogue Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Somatostatin Analogue Drug Market Share by Application: 2025 VS 2032 Figure 9. Acromegaly Image Figure 10. Neuroendocrine Tumor (NET) Image Figure 11. Others Image Figure 12. Global Somatostatin Analogue Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 14. Global Somatostatin Analogue Drug Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Somatostatin Analogue Drug Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Somatostatin Analogue Drug Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Somatostatin Analogue Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Somatostatin Analogue Drug Revenue Market Share by Type (2021-2032) Figure 21. Global Somatostatin Analogue Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Somatostatin Analogue Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 24. North America Somatostatin Analogue Drug Market Share by Type (2021-2032) Figure 25. North America Somatostatin Analogue Drug Market Share by Application (2021-2032) Figure 26. North America Somatostatin Analogue Drug Market Share by Country (2021-2032) Figure 27. United States Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 28. Canada Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 30. Europe Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 31. Europe Somatostatin Analogue Drug Market Share by Type (2021-2032) Figure 32. Europe Somatostatin Analogue Drug Market Share by Application (2021-2032) Figure 33. Europe Somatostatin Analogue Drug Market Share by Country (2021-2032) Figure 34. Germany Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 35. France Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 37. Italy Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 38. Russia Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 40. China Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 41. China Somatostatin Analogue Drug Market Share by Type (2021-2032) Figure 42. China Somatostatin Analogue Drug Market Share by Application (2021-2032) Figure 43. Asia Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 44. Asia Somatostatin Analogue Drug Market Share by Type (2021-2032) Figure 45. Asia Somatostatin Analogue Drug Market Share by Application (2021-2032) Figure 46. Asia Somatostatin Analogue Drug Market Share by Country (2021-2032) Figure 47. Japan Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 51. India Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 52. Australia Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Somatostatin Analogue Drug Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Somatostatin Analogue Drug Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Somatostatin Analogue Drug Market Share by Country (2021-2032) Figure 57. Brazil Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 62. UAE Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 64. Chile Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Octreotide
  • Lanreotide
  • Pasireotide
Applications
  • Acromegaly
  • Neuroendocrine Tumor (NET)
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Eli Lilly & Co.
  • Pfizer Inc.
  • Tarveda Therapeutics Inc.
  • Ipsen Group
  • F. Hoffmann-La Roche Ltd.
  • Chiasma
  • Camurus AB
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Somatostatin Analogue Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Octreotide
  5. 1.2.3 Lanreotide
  6. 1.2.4 Pasireotide
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Somatostatin Analogue Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Acromegaly
  10. 1.3.3 Neuroendocrine Tumor (NET)
  11. 1.3.4 Others
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Somatostatin Analogue Drug Growth Trends by Region
  14. 1.5.1 Global Somatostatin Analogue Drug Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Somatostatin Analogue Drug Market Size by Region (2021-2026)
  16. 1.5.3 Somatostatin Analogue Drug Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Somatostatin Analogue Drug Market Dynamics
  1. 2.1 Somatostatin Analogue Drug Industry Trends
  2. 2.2 Somatostatin Analogue Drug Industry Drivers
  3. 2.3 Somatostatin Analogue Drug Industry Opportunities and Challenges
  4. 2.4 Somatostatin Analogue Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Somatostatin Analogue Drug Revenue by Company (2021-2026)
  2. 3.2 Global Somatostatin Analogue Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Somatostatin Analogue Drug Key Company Head office and Area Served
  4. 3.4 Global Somatostatin Analogue Drug Company, Product Type & Application
  5. 3.5 Global Somatostatin Analogue Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Somatostatin Analogue Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Somatostatin Analogue Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Somatostatin Analogue Drug Tier 1, Tier 2, and Tier 3
4 Somatostatin Analogue Drug Market by Type
  1. 4.1 Global Somatostatin Analogue Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Somatostatin Analogue Drug Market Size by Type (2021-2032)
  3. 4.3 Global Somatostatin Analogue Drug Market Size Share by Type (2021-2032)
5 Somatostatin Analogue Drug Market by Application
  1. 5.1 Global Somatostatin Analogue Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Somatostatin Analogue Drug Market Size by Application (2021-2032)
  3. 5.3 Global Somatostatin Analogue Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Teva Pharmaceutical Industries Ltd.
  2. 6.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 6.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 6.1.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product Portfolio
  6. 6.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 6.2 Novartis AG
  8. 6.2.1 Novartis AG Company Information
  9. 6.2.2 Novartis AG Business Overview
  10. 6.2.3 Novartis AG Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Novartis AG Somatostatin Analogue Drug Product Portfolio
  12. 6.2.5 Novartis AG Recent Developments
  13. 6.3 Eli Lilly & Co.
  14. 6.3.1 Eli Lilly & Co. Company Information
  15. 6.3.2 Eli Lilly & Co. Business Overview
  16. 6.3.3 Eli Lilly & Co. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Eli Lilly & Co. Somatostatin Analogue Drug Product Portfolio
  18. 6.3.5 Eli Lilly & Co. Recent Developments
  19. 6.4 Pfizer Inc.
  20. 6.4.1 Pfizer Inc. Company Information
  21. 6.4.2 Pfizer Inc. Business Overview
  22. 6.4.3 Pfizer Inc. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Pfizer Inc. Somatostatin Analogue Drug Product Portfolio
  24. 6.4.5 Pfizer Inc. Recent Developments
  25. 6.5 Tarveda Therapeutics Inc.
  26. 6.5.1 Tarveda Therapeutics Inc. Company Information
  27. 6.5.2 Tarveda Therapeutics Inc. Business Overview
  28. 6.5.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product Portfolio
  30. 6.5.5 Tarveda Therapeutics Inc. Recent Developments
  31. 6.6 Ipsen Group
  32. 6.6.1 Ipsen Group Company Information
  33. 6.6.2 Ipsen Group Business Overview
  34. 6.6.3 Ipsen Group Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Ipsen Group Somatostatin Analogue Drug Product Portfolio
  36. 6.6.5 Ipsen Group Recent Developments
  37. 6.7 F. Hoffmann-La Roche Ltd.
  38. 6.7.1 F. Hoffmann-La Roche Ltd. Company Information
  39. 6.7.2 F. Hoffmann-La Roche Ltd. Business Overview
  40. 6.7.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product Portfolio
  42. 6.7.5 F. Hoffmann-La Roche Ltd. Recent Developments
  43. 6.8 Chiasma
  44. 6.8.1 Chiasma Company Information
  45. 6.8.2 Chiasma Business Overview
  46. 6.8.3 Chiasma Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Chiasma Somatostatin Analogue Drug Product Portfolio
  48. 6.8.5 Chiasma Recent Developments
  49. 6.9 Camurus AB
  50. 6.9.1 Camurus AB Company Information
  51. 6.9.2 Camurus AB Business Overview
  52. 6.9.3 Camurus AB Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Camurus AB Somatostatin Analogue Drug Product Portfolio
  54. 6.9.5 Camurus AB Recent Developments
  55. 6.10 Boehringer Ingelheim International GmbH
  56. 6.10.1 Boehringer Ingelheim International GmbH Company Information
  57. 6.10.2 Boehringer Ingelheim International GmbH Business Overview
  58. 6.10.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product Portfolio
  60. 6.10.5 Boehringer Ingelheim International GmbH Recent Developments
7 North America
  1. 7.1 North America Somatostatin Analogue Drug Market Size (2021-2032)
  2. 7.2 North America Somatostatin Analogue Drug Market Size by Type
  3. 7.2.1 North America Somatostatin Analogue Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America Somatostatin Analogue Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America Somatostatin Analogue Drug Market Share by Type (2021-2032)
  6. 7.3 North America Somatostatin Analogue Drug Market Size by Application
  7. 7.3.1 North America Somatostatin Analogue Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America Somatostatin Analogue Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America Somatostatin Analogue Drug Market Share by Application (2021-2032)
  10. 7.4 North America Somatostatin Analogue Drug Market Size by Country
  11. 7.4.1 North America Somatostatin Analogue Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Somatostatin Analogue Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America Somatostatin Analogue Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America Somatostatin Analogue Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Somatostatin Analogue Drug Market Size (2021-2032)
  2. 8.2 Europe Somatostatin Analogue Drug Market Size by Type
  3. 8.2.1 Europe Somatostatin Analogue Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe Somatostatin Analogue Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe Somatostatin Analogue Drug Market Share by Type (2021-2032)
  6. 8.3 Europe Somatostatin Analogue Drug Market Size by Application
  7. 8.3.1 Europe Somatostatin Analogue Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe Somatostatin Analogue Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe Somatostatin Analogue Drug Market Share by Application (2021-2032)
  10. 8.4 Europe Somatostatin Analogue Drug Market Size by Country
  11. 8.4.1 Europe Somatostatin Analogue Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Somatostatin Analogue Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe Somatostatin Analogue Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe Somatostatin Analogue Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Somatostatin Analogue Drug Market Size (2021-2032)
  2. 9.2 China Somatostatin Analogue Drug Market Size by Type
  3. 9.2.1 China Somatostatin Analogue Drug Market Size by Type (2021-2026)
  4. 9.2.2 China Somatostatin Analogue Drug Market Size by Type (2027-2032)
  5. 9.2.3 China Somatostatin Analogue Drug Market Share by Type (2021-2032)
  6. 9.3 China Somatostatin Analogue Drug Market Size by Application
  7. 9.3.1 China Somatostatin Analogue Drug Market Size by Application (2021-2026)
  8. 9.3.2 China Somatostatin Analogue Drug Market Size by Application (2027-2032)
  9. 9.3.3 China Somatostatin Analogue Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Somatostatin Analogue Drug Market Size (2021-2032)
  2. 10.2 Asia Somatostatin Analogue Drug Market Size by Type
  3. 10.2.1 Asia Somatostatin Analogue Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia Somatostatin Analogue Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia Somatostatin Analogue Drug Market Share by Type (2021-2032)
  6. 10.3 Asia Somatostatin Analogue Drug Market Size by Application
  7. 10.3.1 Asia Somatostatin Analogue Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia Somatostatin Analogue Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia Somatostatin Analogue Drug Market Share by Application (2021-2032)
  10. 10.4 Asia Somatostatin Analogue Drug Market Size by Country
  11. 10.4.1 Asia Somatostatin Analogue Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Somatostatin Analogue Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia Somatostatin Analogue Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia Somatostatin Analogue Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Somatostatin Analogue Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Somatostatin Analogue Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Somatostatin Analogue Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Somatostatin Analogue Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst